Type 3 Diabetes: Why Alzheimer’s May Be a Metabolic Disease & What That Means for Your Cognitive Performance
Type 3 Diabetes: Why Alzheimer’s May Be a Metabolic Disease
And what that means for your cognitive performance
A growing body of research points to Alzheimer’s not as a neurological accident, but as the end-stage of decades of unmanaged metabolic dysfunction. Here is what executives in their forties need to understand now.
For most of medical history, Alzheimer’s disease was framed as abnormal protein buildups in the brain: accumulation of amyloid-beta plaques, formation of tau tangles, which damage and destroy neurons. The disease progresses inexorably, and there is little to be done about it.
This framing is now being challenged, with significant implications not just for patients in their seventies, but also for executives in their forties operating under chronic stress.
A growing body of research in neuroscience and metabolic medicine points to a different account of how Alzheimer’s begins: not as a neurological accident, but as the end-stage of decades of unmanaged metabolic dysfunction. Specifically, the failure of insulin signalling within brain tissue, a phenomenon now termed, by a number of researchers in the field, Type 3 Diabetes.
What Mainstream Medicine Got Wrong About Alzheimer’s
The protein aggregation model, amyloid-beta and tau as the primary cause of neurodegeneration, dominated Alzheimer’s research for decades and produced a long sequence of failed clinical trials. Drugs that successfully cleared amyloid plaques in trial conditions consistently failed to improve or slow cognitive decline in patients.
This failure prompted a critical question that the field had largely deferred: why do these proteins accumulate in the first place?
The answer that has emerged from researchers including teams at the National Institute on Ageing, and those studying what has been called the Bioenergetic Failure Model of neurodegeneration, reframes the disease entirely. Under this model, Alzheimer’s is not primarily a disease of protein accumulation. It is primarily a disease of energy failure at the cellular level, with protein accumulation as a downstream consequence of neurons that can no longer produce or utilise energy efficiently.
The Insulin-Brain Axis: The Critical Implication for Executives
The brain is not insulin-independent. It expresses insulin receptors at high density throughout the hippocampus, the prefrontal cortex (PFC), the hypothalamus, and the entorhinal cortex, the precise regions involved in memory consolidation, executive function, and the earliest stages of Alzheimer’s pathology.
Insulin in the brain does not primarily regulate glucose uptake the way it does in peripheral tissue. Its roles are more nuanced: it modulates synaptic plasticity, supports neuronal survival, regulates inflammation, and facilitates the clearance of amyloid-beta. When insulin signalling in these regions becomes impaired, when neurons become insulin-resistant, each of these functions degrades.
This is the mechanism behind the Type 3 Diabetes hypothesis, first formally articulated by a researcher at Brown University. The brain develops its own form of insulin resistance, independent of, though often correlated with, systemic Type 2 diabetes. Post-mortem studies of Alzheimer’s patients consistently show significantly reduced insulin receptor density and impaired insulin signalling in affected brain regions compared to age-matched controls without dementia.
The Stress-Cortisol-Insulin Connection: Why High-Pressure Roles Accelerate the Risk
The connection between executive stress and metabolic dysfunction is direct, not metaphorical, and the pathway is well-characterised.
Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, driving sustained elevation of cortisol. Cortisol’s metabolic effects are significant: it directly stimulates hepatic glucose production, promotes peripheral insulin resistance, and, with chronic elevation, suppresses the brain regions responsible for inhibiting the stress response in the first place. It is a self-reinforcing cycle.
A 2023 study found that C-suite executives reporting high occupational stress had fasting insulin levels approximately 34% higher than age-matched low-stress controls. Elevated fasting insulin is among the earliest and most reliable markers of insulin resistance, detectable years before blood glucose levels become abnormal, and rarely included in standard executive health check-ups.
The prefrontal cortex, the seat of strategic cognition, impulse control, working memory, and the decision-making capacity that executives are ultimately paid for, is one of the most metabolically demanding and least resilient structures in the brain. It is also among the first regions to show functional impairment under conditions of energy insufficiency.
Ketone Bodies, Nutrition and Neuroprotection
One of the most clinically significant findings of the bioenergetic model is that neurons impaired in their ability to utilise glucose can, in many cases, still efficiently metabolise ketone bodies, an alternative fuel substrate derived from fat, produced during periods of fasting or carbohydrate restriction.
A 2024 meta-analysis confirmed that mild ketosis, achieved through dietary means, was associated with improved cognitive performance scores in adults with mild cognitive impairment and metabolic risk factors. The proposed mechanisms include improved mitochondrial efficiency, reduced neuroinflammation, and restoration of energy availability in neurons that have become glucose-resistant.
The practical dietary strategies with the strongest evidence base in this context are:
Time-Restricted Eating (TRE)
Confining food intake to a consistent 8 to 10 hour window each day reduces fasting insulin, improves metabolic flexibility, and extends the overnight fasting period during which ketone production is elevated. This is accessible without requiring significant dietary change.
Carbohydrate Quality Management
Reducing refined carbohydrates and ultra-processed food, the primary drivers of postprandial glucose spikes and compensatory hyperinsulinaemia, is the most impactful single nutritional variable for fasting insulin control.
Medium-Chain Triglyceride (MCT) Supplementation
MCTs are converted to ketone bodies in the liver independent of fasting state, providing a direct alternative fuel source for the brain. Evidence from studies including a 2004 trial published in Neurobiology of Ageing suggests measurable improvements in cognitive performance in at-risk populations following MCT supplementation, with effects appearing within hours of a single dose.
The Health Metric You Should Be Tracking and Probably Are Not
Standard executive health checks measure fasting glucose, total cholesterol, and blood pressure. These are late indicators. By the time fasting glucose is elevated, insulin resistance has typically been present for five to ten years.
Detects insulin resistance years before blood glucose becomes abnormal. Rarely included in standard panels.
A calculated index of insulin resistance derived from fasting insulin and glucose. The most accessible early marker of metabolic dysfunction.
A reliable proxy for insulin resistance. A ratio above 2.0 is associated with significantly elevated metabolic risk.
Your Next Step
Do not wait for symptoms. Schedule a comprehensive metabolic assessment within the next 30 days and review the following:
Then identify one metabolic habit to improve over the next 30 days, whether that is time-restricted eating, better sleep, improved nutrition, or stress management.
Because protecting your long-term cognitive performance does not start with your calendar. It starts with your biology.
Executive Health and Performance Advisory
Your metabolic health is either protecting your cognitive performance or eroding it. Let us find out which.
Our Executive Health and Performance Advisory includes comprehensive metabolic assessment, fasting insulin testing, HOMA-IR analysis, and a personalised protocol to restore insulin sensitivity and protect long-term brain health.
Explore Executive AdvisoryDisclaimer
The information presented in this article is intended for general educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. References to “Type 3 Diabetes” reflect emerging hypotheses in metabolic medicine research and are not universally adopted clinical terminology. The content reflects the views of the author based on available scientific literature and professional experience. Individual health conditions vary significantly. Before making any changes to your diet, supplementation, or clinical testing routine, consult a qualified healthcare professional. Deep-Health does not endorse specific diagnostic tests, products, or treatment protocols without a prior individual assessment. References to scientific studies are included for context; outcomes may differ between individuals. This content is not a substitute for professional medical advice.
Sanjay Dev
Founder of Deep-Health. 20-plus years working with founders, executives, athletes, and organisations at the intersection of neuroscience, physiology, and behavioural biochemistry.
View all articles by Sanjay